NEWS: Our Blog

Dive into the world of Resolian with our video series featuring our CEO Patrick Bennett

Jan 10, 2024 8:00:00 AM / by Resolian posted in CEO, Bioanalysis, Growth, Resolian

hs_newPatrickExplore the history that shaped Resolian and get a sneak peek into our future plans with our new video series. 

In the series of nine videos our CEO, Patrick Bennett explains the journey behind our recent rebranding and future plans in an insightful interview with Chris O'Connor from Life Science Marketing Radio.


Chapter 1 - "We Are Resolian"

Discover the journey behind our recent rebranding directly from our CEO, Patrick Bennett, in an insightful interview with Chris O'Connor from Life Science Marketing Radio.

Get ready for an exclusive look into the heart of Resolian, as we share our resolution to be one of the best laboratories globally committed to our purpose and mission in serving customers and our scientific staff.

🎬 Watch the video here: 


Chapter 2 - "One Global Organization"

Our journey into becoming a unified global entity in just 15 months has set the stage for unparalleled flexibility and efficiency. The decision to consolidate under one name allows the organization to function seamlessly as a single entity, providing clients with the flexibility to manage clinical trials across the strategically located laboratories in the US, Europe, China, and Australia.

🎬 Watch the video below.


Chapter 3 - "Empowering Global Collaboration"

The acquisition of China-based Denali Medpharma in November 2023 marks a significant leap forward in our global capabilities, particularly benefiting clients navigating the complexities of the Chinese market.

With a team of high-quality scientists, the lab brings valuable expertise, bridging the gap for companies unfamiliar with the intricacies of operations in China. Our unique advantage lies in seamless method transfers between Western pharma clients and the China lab.

🎬 Watch the video here to find out more about what the new lab in China means for our clients.

Read more about the Resolian acquisition of Denali Medpharma here: 

Chapter 4 - "Australia Lab - Accelerating Success"

The Australia lab emerges as a game-changer for clients seeking accelerated timelines and financial advantages in early-phase clinical studies. The regulatory landscape in Australia facilitates faster initiation of first-in-human studies compared to the US and Europe, supported by a network of robust clinical facilities.

Beyond speed, there is also a financial benefit to conducting trials in Australia.

Companies can claim 43.5% R&D cash refund with the Australian Government clinical trial rebate program, delivering a dual advantage in both efficiency and finance.

🎬 Watch the video here to find out more about Resolian’s Australian lab.

Chapter 5 - "Logistics Mastery for Seamless Global Operations"

Handling samples across borders involves intricate considerations, from stability to hazards. Resolian's expertise shines in navigating these complexities, particularly evident in China where HGRAC regulations pose challenges to the movement of human-based samples.

🎬 Watch the video here to find out more about Resolian’s logistics capabilities.


Chapter 6 - "Tailored Solutions for Sponsors"

Sponsors often manage a portfolio of vendors. Most want to have some larger full-service companies in their portfolio of bioanalytical vendors. Depending on the project, those full-service vendors aren’t always the right fit. Most of them are not global. A sponsor might take advantage of one component of their service but are not necessarily what you need for this specific project.

There is always a need for laboratories like Resolian that are focused on bioanalysis.

🎬 Watch the video here to find out more about Resolian’s responsiveness and flexibility.


Chapter 7 - "Diverse Analytical Prowess Unveiled"

Unlocking the depths of Resolian's analytical capabilities reveals a remarkable breadth across various specialties. While many labs excel in specific areas, each of Resolian's entities stands out for its comprehensive strength. With extensive experience ranging from immunoassay to LCMS, including small molecules, large molecules, biologics, and oligonucleotides, Resolian covers a spectrum of analytical domains.

🎬 Watch the video here to find out more about the diverse analytical skills at Resolian.


Chapter 8 - "Balancing Unity and Uniqueness"

Four bioanalytical labs, four continents.

Navigating the question of maintaining consistency, Resolian unveils a dual approach to harmonize operations seamlessly. While integration is implemented for non-scientific functions, ensuring universal policies with local modifications, the scientific operations follow a unique path of harmonization.

🎬 Watch the video here to find out more about our goal to create a familiar environment for legacy customers, facilitating flexibility between geographies.


Chapter 9 - "Unveiling the Heartbeat - Bringing Benefits to Patients!”

In this final instalment, we explore Resolian's impact on patients' experiences in clinical trials. Unlike central labs or clinical diagnostics, bioanalysis often involves unique methods, limiting optimal locations for sample analysis.

Resolian's global network, with laboratories in multiple geographies, provides our pharma clients the leverage to strategically choose where they run analyses in alignment with their clinical trials. This not only expands the options for clients but, more importantly, broadens the reach of clinical trials, benefiting a larger population of patients around the globe.


Read More

8 Essential Characteristics of LC-MS/MS Method Validation

Jul 4, 2023 12:01:32 PM / by Alliance Pharma posted in Pharmaceuticals, lc-ms/ms


Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a powerful technique in the field of bioanalysis, and it plays a critical role in drug development and clinical trials. This method has a well-earned reputation for high selectivity, sensitivity, and specificity for the detection and quantification of low levels of target analytes in complex matrices. The development and validation of a new LC-MS/MS bioassay is a complex and demanding process that involves assessing its performance via analytical characteristics. Even experienced scientists can face pitfalls when developing and validating a new bioassay, so to ensure that the LC-MS/MS method is reliable and accurate, it is essential to validate the method.

Here, we will summarize the eight essential characteristics of LC-MS/MS method validation, then explain why it is important that you work with an experienced contract research organization (CRO) to ensure quality in each of these areas: 

  1. Accuracy
  2. Precision
  3. Specificity
  4. Quantification Limit
  5. Linearity
  6. Recovery
  7. Matrix Effect
  8. Stability 

1. Accuracy

Accuracy refers to the difference between the measured value and the true value of the analyte. Scientists assess the accuracy of an LC-MS/MS method by comparing the measured concentration of the analyte in the sample to the known concentration of the analyte in a standard solution. Even small inaccuracies can lead to significant errors in the final concentration of the analyte, resulting in ill-informed decisions and, potentially, the risk of underdosing or overdosing a patient.

2. Precision 

In LC-MS/MS method validation, precision refers to the degree of agreement between the results obtained through multiple measurements of the same sample under the same conditions, and it is assessed by calculating the variability of these results. Precise results are essential for reducing uncertainty in the final concentration of the analyte and ensuring the reproducibility of the method.

3. Specificity

Specificity refers to the ability of the method to accurately measure the target analyte in the presence of other sample components. This can be assessed by analyzing samples that contain the analyte of interest as well as other potentially interfering substances. Specificity is essential in LC-MS/MS method validation because it ensures that the method can accurately measure the analyte of interest without interference from other components in the sample.

4. Quantification Limit

The quantification limit is the lowest concentration of the analyte that can be reliably and accurately measured by the method. This is determined by analyzing samples with decreasing concentrations of the analyte until the signal-to-noise ratio (S:N) reaches a predefined level (20:1 to enable an increased chance it will be suitable). Defining the quantification limit is key because it provides an idea of what sort of sample extraction technique is needed, as well as determining the sensitivity of the method and the lowest concentration that can be reported. These are crucial to ensuring the accuracy of your results.

5. Linearity

Linearity is the ability of the method to produce results that are directly proportional to the analyte concentration over a defined range. In LC-MS/MS method validation, linearity is determined by analyzing samples with increasing concentrations of the analyte and plotting the response against the concentration. Linearity is essential because it ensures that the method can accurately measure a wide range of analyte concentrations. 

6. Recovery

Recovery refers to the ability of the method to accurately measure the analyte in the sample after the sample has undergone extraction or other sample preparation procedures. Recovery is assessed by spiking the sample with a known amount of the analyte and comparing the measured value to the expected value. This process is essential because it determines the accuracy of the method for your specific sample matrix.

7. Matrix Effect

Matrix effect is the interference caused by the sample matrix on the ionization and detection of the analyte. Matrix effect is evaluated by comparing the response of the analyte in the sample matrix to its response in a pure solvent. The method should be able to accurately measure the analyte in the presence of the sample matrix without interference. This is essential because interference from the sample matrix or metabolites can impact the accuracy and precision of the method and cause variations in the analyte concentration. Careful validation is essential for optimizing methods that eliminate or minimize these risks.

8. Stability

Stability is the ability of the analyte to remain stable in the sample matrix under the conditions of storage and processing over time. It is evaluated by analyzing the samples at different time intervals and temperatures and comparing the results, across which the analyte should remain stable. Stability is essential to ensure that the method can provide accurate, reliable and consistent results.

The Key to Quality in All Eight Areas

Developing and validating a new bioassay using LC-MS/MS is a complex process that requires expensive instrumentation, advanced software, and, most importantly, tremendous expertise. Your CRO partner should have a team of scientists with the depth of expertise in LC-MS/MS method development and validation to ensure excellence in each of the eight essential categories listed above. To do this successfully, they should have access to state-of-the-art instrumentation and analytical techniques and be able to guarantee that the bioassay meets all regulatory requirements. That is the way to ensure that the method is carefully optimized and validated for your specific sample matrix, delivering the insights needed to make confident decisions for your program.

In the biopharmaceutical industry, LC-MS/MS assays require accurate, precise, and robust methods developed in the shortest time possible. At the UK lab of Resolian, we have successfully employed a protocol that reaches these goals consistently and efficiently. This achievement has enhanced our capabilities across the Resolian organization: Fordham and Sandwich (U.K.); Malvern, PA (USA); Brisbane (AUS).

Read the guide to discover our powerful approach to developing LC-MS/MS bioassays.

Read More

Australia Advantage – Consider Conducting Clinical Trials in Australia

Mar 16, 2023 11:33:42 AM / by Alliance Pharma posted in Pharmaceuticals, Immunoassay, bioanalytical, laboratory, Quality, Large Molecule, Bioanalysis, DMPK, Australia


Our advanced scientific infrastructure and world-class experts attract trials from across the globe and meet their needs with the highest standards and efficient regulatory requirements.

Explore the extensive benefits of Australia’s clinical research ecosystem below.

    Alliance Pharma has a world-class reputation for quality data, following the highest level of GCP and ICH standards. Data from clinical trials conducted in Australia is widely accepted by all regulatory authorities including FDA and EMA.

     includes bioanalytics services
     almost halve your clinical trial costs

    You can claim R&D cash refund with the Australian Government clinical trial rebate program. As an example, if you spend $200k on eligible R&D, you can receive $87k (43.5%) back from the Australian Tax Office (ATO). This effectively means you could turn $1million dollars into $1.7 million dollars of research spend in just three years.

     The Australian Regulatory Framework is the fastest in the world for undertaking early phase clinical research trials
     Trials can start in 4-8 weeks compared to 10 months in the US.
     No IND required for clinical trials. Save up to a year in regulatory timelines and considerable costs.

    Clinical trials are resource-intensive processes requiring the availability of state-of-the-art equipment and facilities for testing and analysis. We have invested heavily in the industry-leading technology platforms to support speed, communications, and regulatory compliance.

    Local relationships, global execution As a global contract research organization – with sites in USA and UK – we can provide internal assay transfer and validation protocols among our global sites.

    Harmonized SOPs, policies, and IT systems to facilitate transfer of methods, data, and information enable you to reduce time, risk, and cost.

    Seasonal differences to Europe and US, and time differences (our Australia lab works while you sleep)Seasonal differences between Australia and Europe or the US allow for yearlong participant recruitment for trials involving seasonal illnesses such as flu or allergies and allows researchers to cover seasonal variations in patient recruitment.

    Australian clinical practices and some aspects of its health care system are similar to the United States, United Kingdom and most of Europe.

    The willingness of potential participants and their knowledge of clinical trials is another attractive option for sponsors to conduct trials in Australia.

    A mixed population of Caucasians and Asian adds diversity to the participant pool and enables ethnicity differences in treatment response to be studied.

Need Support to Conduct Clinical Trials in Australia?  Contact Alliance!




Read More

ICT Autumn 2022: How To Build a Comprehensive Response to Client Needs as a CRO

Nov 28, 2022 12:45:23 PM / by Alliance Pharma posted in Pharmaceuticals, Leadership, Philadelphia, bioanalytical, Quality, Drug Transporter, Bioanalysis, DMPK, AMS

EPC CRO _png4
As a CRO, meeting client expectations can be an ongoing challenge. What can organisations do to make sure their research is as effective and efficient as possible?

In the Autumn 2022 issue of European Pharmaceutical Contractor magazine, the leadership team from Alliance Pharma reviews what CRO organisations can do to make sure their research is as effective and efficient as possible while meeting the ongoing challenge of their customer's expectations.

Patrick Bennett, Jean Pierre Boutrand, and Vito Saccente at Alliance Pharma

Serving clients is the core of a contract research organisation’s (CRO) business. The more comprehensive a CRO’s service offerings, the more likely it is to attract and retain clients. Recent events – like the COVID-19 pandemic – have set in motion industry shifts. Such shifts demand CROs adapt so that they can continue meeting their clients’ evolving needs . . .



Read More


Aug 26, 2022 8:46:13 AM / by Alliance Pharma posted in Philadelphia, DDI Assessment, Drug Transporter, DMPK

Membrane transporters play a critical role in drug-drug interactions (DDIs). Both major types of transporters — efflux and uptake — can affect absorption and drug disposition in the body. Transporters can impact drug safety and efficacy, acting alone or in concert with drug-metabolizing enzymes.

The picture of what is happening in the body gets increasingly murky when patients take more than one drug, which is increasingly common. To obtain insights of how DDIs occur and what their consequences might be, it is vital to conduct in vitro studies and generate the data required to determine whether clinical DDI studies are needed. This is an area where Alliance excels.

In Vitro Assessment of a Transporters’ Potential Role in DDIs

The full picture of a new drug’s DDI potential involves to determine:

  • How a new drug is absorbed and eliminated
  • How enzymes and transporters contribute to its disposition
  • How to characterize the drug’s effects on enzymes and transporters

Properly designed in vitro transporter studies can support a prediction of whether a DDI through transporters is likely to be clinically relevant, and Alliance has all the tools needed to thoroughly evaluate potential transporter mediated DDIs. We use Caco-2 cells expressing efflux transporters such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), HEK293 cells transfected with uptake or efflux transporters including OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1 and MATE2k, MDR1-MDCKII cells, and HEK293 membrane vesicles expressing P-gp, BCRP and BSEP to study transporters, which are outlined in FDA and EMA guidelines.

Helping Clients Solve Problems and Make Decisions

Our clients’ primary need regarding drug transporters is to determine whether their drug candidate is a substrate or inhibitor of a transporter, and if that is clinically relevant. Clients need to know (1) when to do these experiments and (2) how comprehensive the experiments need to be.

(1) In a clinical program, it is crucial to know when to address questions about transporter mediated drug-drug interactions. That decision is driven by the clinical study design and the timing of the in vitro evaluation — which itself can vary based on the therapeutic indications of the investigational drug. For example, if the intended population is likely to use statins, the sponsor should examine their investigational drug’s potential to interact with OATP1B1/1B3 before initiation of clinical studies in patients. Without a question, the co-medications patients are taking factor heavily, so companies must decide how restrictive they want their studies to be. To avoid these transporter studies early on (Phase I), companies can recruit and enroll only healthy volunteers with no current co-meds prescribed to them. However, when a drug is to be administered to the target patient population — patients actually affected by the disease the drug is being developed to treat — it is critical to consider issues such as co-meds, potential renal or other impairments, and the transporters of which the new drug is a substrate and/or inhibitor.

(2) The comprehensiveness of a transporter study is influenced by the relationship between predicted in vivo drug concentrations and the concentrations at which the drug is interacting with the transporter in vitro. For example, if you have a drug that is an inhibitor at a very high concentration, but that concentration will never be reached in the clinic, you might be able to justify forgoing additional testing. (FDA decision trees for this and related questions are available here.) In vivo protein binding and the free fraction of drug in the in vitro system are important data points also to understand and characterize. These are the kinds of decisions Alliance helps our clients make.

The Key Factors in Choosing a Suitable In Vitro Test System

The appropriate model for in vitro testing depends on the desired output. For example, if you need a rapid turnaround but don’t require detailed characterization of a transporter interaction, rapid screening assays are sufficient. For more comprehensive characterization to determine whether to conduct a DDI study, HEK 293 singly transfected cells or the Caco-2 cell line are very useful for characterizing the kinetics of an interaction in detail and can be used to get the output needed. Choosing the right model to deliver the most accurate prediction of how a new drug will behave in vivo is a critical step.

Validating a Model and Experimental Conditions

Know inhibtiors and substrates are used to validate the transporter study models and experimental conditions and characterize assay performance. In other words, the most well-characterized substrates in the literature — substrates that have been studied in vitro and in vivo — are used to establish the assay initially, and then the assay quality is consistently evaluated to determine that the assays are running properly. This approach allows us to build up a history of in house data and continuously assess model performance.

How Alliance Stands Out in This Area

Alliance’s range of models from cell lines to singly transfected systems provides diverse options for our clients and provides rapid turnaround or comprehensive kinetic characterization. With these models and expertise, Alliance Drug Metabolism Services is able to help our clients answer their most challenging and important questions. The bioanalytical support from the strong Bioanalytical teams at Alliance ensure the study data integrity and dependable timelines. Very few of our competitors have this diversity of models up and running routinely, setting us apart.

One unique advantage for Alliance is our in-house expertise using Caco-2 cells. This is a polarized cell line expressing efflux transporters such as P-gp, BCRP and MRP2 that is physiologically similar to human small intestine cells, making it relevant to in vivo studies. The Caco-2 cell model is a valuable tool for evaluating P-gp and BCRP-mediated transport and assessing potential DDIs.

When it comes to DDIs, drug transporters continues to evolve, and new transporters are frequently identified. More and more drug transporters have been found to be clinically relevant. Alliance is always ready to adopt and implement new models when transporters are identified as physiologically relevant to human. We also have the expertise to characterize new transporter study models lacking of regulatory guidance, for example, our recent adoption of a bile salt export pump (BSEP) model, which does not yet appear in FDA guidance.

Alliance’s team members have a unique and deep understanding on how transporter-mediated DDI studies should be designed and executed. We understand how transporters behave, how they interact, and how they can cause clinically relevant DDIs. Whether a new potential drug is at the early discovery stage or the late developmental stage, Alliance can help our clients in the transporter studies. Visit the Alliance website to explore our capabilities and expertise.

Read More

Ampersand Invests in Alliance Pharma, Leading Bioanalytical CRO

Nov 19, 2021 10:23:36 AM / by Ryan Klein posted in Leadership, Feng Li, CEO, success, Growth

WELLESLEY, MA, November 18, 2021 /PRNewswire/ -- Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector, has announced an investment in Alliance Pharma (“Alliance”), a global leader in large and small molecule bioanalytical services. Headquartered in Malvern, PA., Alliance provides a full suite of discovery bioanalytical, DMPK, regulated bioanalysis, biomarker, LC-MS/MS, immunoassay, and cell and gene therapy assays. These capabilities support preclinical-through-Phase 4 studies run by a global customer base comprised of leading pharma and biotech companies.

Dave Patteson, Partner at Ampersand, stated "We are very excited to complete this investment in Alliance and partner with Founder and President Frank Li, who will remain a significant shareholder in the Company. Ampersand’s goal is to help Alliance execute an aggressive growth strategy that will expand the Company’s global reach, scientific capabilities, and operational capacity.”

Frank Li, President of Alliance, stated "We are delighted to have Ampersand invest in Alliance. Ampersand’s deep industry expertise, broad network, and capital resources will fortify Alliance Pharma’s position as a market-leading global specialty CRO."

About Alliance Pharma

Founded in 2008, Alliance is a contract research organization (CRO) that specializes in advanced bioanalytical research services for both small and large molecule drugs, as well as drug metabolism studies to support pharmaceutical and biotechnology companies’ drug discovery and development programs. Alliance Pharma provides: quantitative LC-MS/MS analysis of small molecule drugs, metabolites, biomarkers, protein, peptides and oligonucleotides, as well as immunoassay of proteins and antibody drug conjugates; immunogenicity assays (anti-drug antibody screening, confirmation, titer assessment, and Nab determination): cell-based bioassays; in vitro and in vivo drug metabolism and pharmacokinetic studies.

Alliance’s mission is to build a trusted partnership with our partners & clients to support their successful drug development programs. Alliance’s business philosophy is based on a foundation of trust, professional ethics, scientific excellence and regulatory compliance.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. Additional information about Ampersand is available at

Read More

> Our Expansions and Added Resources in 2020

Nov 16, 2020 9:00:00 AM / by Ryan Klein posted in Pharmaceuticals, Conferences, DMPK


How has 2020 treated your company? It has been an odd year to say the least, and we are extremely grateful for the opportunities we have had in our field to work alongside and support companies, such as yours, providing medications to help people live the fullest life possible.

While we have been working with our clients on their exciting projects, we have also been working internally on growing! During the past 12 months we have expanded our footprint and capabilities within our current facility as we continue to build trusted partnerships with you – our clients! We have done this by adding the following:


  • 3,000 square feet of additional office space
  • Three additional laboratories that cover approximately 1,600 square feet
  • OHC 3 – 5 lab facility
  • A BSL3 lab facility will be completed in the fourth quarter of 2020


  • Two Agilent 6495 QqQ LC-MS/MS instruments
  • Two Agilent 8900 Triple Quad ICP-MS instruments
  • Validated Agilent Mass Hunter software
  • Two Sciex 6500+ LC-MS/MS instruments
  • New Gyrolab xPlore
  • Upgraded Watson LIMS to version 7.6.1
  • One Agilent Bio-Inert UHPLC


We have also seen a 15% growth in our staff! We continually look for scientists, lab assistants and techs, IT specialists, software developers, business development/marketing, quality assurance, fellows, and report reviewers for example. We invite you to review our openings on our website and consider joining our role serving the pharmaceutical, biotech, and agrochemical industries, as well as academia.

We look forward to working with you in the months wrapping up 2020 as well as in 2021 with our increased space, resources and staff! Please reach out to us at 610-296-3152 or to discuss how our space, equipment and staff can best meet your drug development and drug metabolism project needs.

Any further questions or need an answer?  Please contact Ryan Klein at or 919-801-3146.

Read More

> Making the Most of Your Virtual Conference Experience

Nov 10, 2020 2:00:00 PM / by Ryan Klein posted in Pharmaceuticals, Conferences, DMPK


Remember when we used to meet in person for our conference experiences? We would gather at conference centers and hotel complexes to attend great seminars, to have insightful conversation, to reconnect with old friends and to make new friends. Everything has changed this year as we all continue to adapt to the COVID-19 pandemic. We understand that many of us are sad about what we may miss, but we are thankful for the technology available that allows us to still attend conferences virtually. We know great interactions, education and conversations can still occur even if it has to happen online!

Our latest blog offers tips on how you can make the most of your virtual conference experience. We hope these tips help you as you adapt to our “new normal”. We look forward to seeing and meeting with you during virtual events in the months ahead. Thank you for the trust you put into us with your drug development and drug metabolism projects!

Tips for attending a virtual conference

We are all used to packing our bags, traveling and preparing for our interactions when it comes to attending conferences. COVID-19, however; has changed all of that this year. As many conferences are turning into virtual events, we thought we’d highlight some ways you can get the most out of your virtual conference experience.

  • Prepare mentally for attending the conference. You don't want to just "show up" online. Be prepared with any prep work you would have done prior to an in-person conference. This includes being aware of any potential distractions surrounding you, including your email and phone notifications. It’s tempting to try and multi-task in this circumstance, but do what you can to stay focused on the meeting, just like you would if you attended in person.

  • Be bold. Just as you wouldn't attend an in-person conference and stay in your room the entire time, except for a session or two, you must also be bold in these virtual settings. That means being willing to ask the questions, make the introductions and network. Many virtual conference platforms are offering video chats. Don’t be afraid to ask someone for a face-to-face call.

  • Be active on social media. Social media is a great tool for staying connected and asking questions before, during and after a virtual conference. If you aren't comfortable asking in a live event, use that hashtag to ask your questions on social media channels. Not sure you want your question in public spaces? Follow the social media channels of the conference host, speakers, panelists, sponsors, vendors and attendees, and use those direct message features or find the contact info for that direct email or phone call.

  • Take time to stroll. At a conference, you may pick up a cup of coffee and stroll through the booth areas. Do the same with virtual booth access. Vendors are supporting the virtual meeting through funding and their presence at the meeting. Provide some support for them by visiting the virtual booth and learning about their services in between presentations and during the times dedicated to the virtual exhibit hall.

  • Be patient! Just as you are learning to now navigate a virtual conference, so are all the other attendees, vendors and hosts. There will be times when technology doesn't work right, people forget to mute themselves or even random hiccups occur. Some of it may even feel awkward. Through it all, remember we are all working to adapt in the midst of all the changes COVID-19 has brought this year.

  • Don’t leave early. That last session or final connection may just be the one that makes a difference for you and your company. Make sure to take full advantage of the entire schedule and resist the temptation to head to the couch early.

You can find our conference schedule on our website and our social media channels. Please remember we may not have a table set up around the corner of the conference hall, but we are here to answer any of your questions and welcome your conversation. Visit us at our virtual booth and chat with our team through the virtual conference links at our scheduled events. You are also always welcome to contact us at 610-296-3152 or

We look forward to seeing you at that next virtual conference!

If you’re going to any upcoming conferences and would like to meet with us, please contact Ryan Klein at or 919-801-3146.

Read More

> POSTERS: 12th International ISSX Meeting

Nov 15, 2019 10:30:00 AM / by Ryan Klein posted in Pharmaceuticals, Conferences, DMPK


Seven hundred scientists, students, and exhibitors convened at the Oregon Convention Center in Portland, Oregon, USA this past July 28–31 for ISSX2019.

Alliance Pharma is proud to have presented the three posters below.
Click poster images below to download a PDF file.






If you’re going to any upcoming conferences and would like to meet with us, please contact Ryan Klein at or 919-801-3146.

Read More

> University of Wisconsin Land O’Lakes DMPK Conference

Sep 6, 2019 10:00:00 AM / by Alliance Pharma posted in Pharmaceuticals, Conferences, DMPK


University of Wisconsin Land O’Lakes DMPK ConferenceThe Land O’Lakes conference series is one of the longest running and most revered teaching conferences in the pharmaceutical industry. Over the last two decades, the Land O’Lakes conferences have been developed by the division of pharmacy professional development within the school of pharmacy at the University of Wisconsin-Madison and have an impeccable reputation within the pharmaceutical industry for shedding light on cutting edge topics, bringing in knowledgeable experts and having an intimate setting which lends itself to some fantastic networking opportunities. 

We at Alliance Pharma are pleased to announce that we will be attending the 22nd annual Land O’Lakes conference on Drug Metabolism and Applied Pharmacokinetics on September 9th thru September 12th in Madison, Wisconsin. We are excited and eager to hear from industry leaders on the new advances in drug delivery, action and metabolism. This years’ meeting is titled ‘Found in Translation: Adaptive DMPK Strategies’, and will include topics focused on target mediated drug disposition (TMDD), endogenous biomarkers and more.

Target mediated drug disposition requires that we think outside the box in terms of drug distribution and elimination from the body. TMDD often exhibits nonlinear pharmacokinetics and pharmacodynamics due to the drugs unusually high affinity to a binding site.

Endogenous biomarker research, particularly in the drug transporter area, continues to rapidly evolve. Our biomarker team at Alliance is a highly experienced team with significant expertise in biomarker method development and analysis, yet we are always eager to learn more!

If you’re going to the conference and would like to meet with us, please contact Ryan Klein at or 919-801-3146.

Read More